Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Early Detection of Cognitive Dysfunction in Diabetes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Wuhan General Hospital of Guangzhou Military Command.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
zhipeng xu, Wuhan General Hospital of Guangzhou Military Command
ClinicalTrials.gov Identifier:
NCT01830998
First received: April 1, 2013
Last updated: April 10, 2013
Last verified: January 2012

April 1, 2013
April 10, 2013
January 2012
January 2014   (final data collection date for primary outcome measure)
MMSE Olfactory function dementia [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
MMSE,Olfactory function and PET(fMRI) were observed.
Same as current
Complete list of historical versions of study NCT01830998 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Early Detection of Cognitive Dysfunction in Diabetes
Study of Cognitive Dysfunction and Diabetes

The rate of cognitive decline due to ageing is increased 1.5-fold to 2.0-fold in individuals with type 2 diabetes.There are no established specific treatment measures to prevent or ameliorate cognitive impairments in patients with diabetes. we want to detecte early clinical dementia in diabete.

Clinically relevant cognitive decrements in relation to diabetes mainly occur during two crucial periods in life: the period of brain development in childhood, and the period when the brain undergoes neurodegenerative changes associated with ageing.Potential leads for treatment are to optimise glycaemic control and avoid and treat vascular risk factors.we want to detecte early clinical dementia in diabete by MMSE and Olfactory function.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   None Retained
Description:

serum

Probability Sample

Patients with type 2 diabetes

  • Dementia
  • Olfactory Function
Not Provided
  • control,MCI, Olfactory dsfunction
    There are different groups:control,MCI, Olfactory dsfunction.
  • control, MCI
    control and MCI group.Glycaemic control
  • control and MCI
    treatment and without treatment
  • MCI and Olfactory function
    observation between MCI and Olfactory function groups.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with type 2 diabetes(Age>50 years)

Exclusion Criteria:

  • with stroke or other complications.
Both
50 Years to 80 Years
Yes
Contact: xuzhipeng Wuqiang lihonghua, doctor 13871168392 21823074@qq.com
China
 
NCT01830998
20130401
No
zhipeng xu, Wuhan General Hospital of Guangzhou Military Command
Wuhan General Hospital of Guangzhou Military Command
Not Provided
Not Provided
Wuhan General Hospital of Guangzhou Military Command
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP